Alprostadil vs TriMix
A side-by-side research comparison of Alprostadil and TriMix across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Alprostadil | TriMix |
|---|---|---|
| Full name | Alprostadil (Prostaglandin E1) | TriMix (Papaverine + Phentolamine + Alprostadil) |
| Category | Sexual Health | Sexual Health |
| Status | FDA-approved drug (prescription) | Compounded medication |
| Mechanism | Alprostadil activates prostaglandin receptors that raise intracellular cAMP in cavernosal smooth muscle, causing vasodilation and increased blood inflow to produce an erection regardless of nerve signaling or arousal. | Papaverine relaxes smooth muscle via PDE inhibition. Phentolamine blocks alpha-adrenergic receptors. Alprostadil (PGE1) directly stimulates cAMP production in cavernosal tissue. Together they produce reliable penile erection independent of arousal. |
| Molecular weight | 354.5 Da | Combination compound |
| Half-life | Very short (minutes, locally metabolized) | ~1-3 hours (local effect) |
| Bioavailability | Intracavernosal injection or intraurethral suppository | Direct intracavernosal: ~100% |
| Typical dose | Provider-titrated per response | 0.1-0.5 mL (titrated) |
| Frequency | As needed before activity | As needed, max 3x/week |
| Route | Intracavernosal injection or urethral pellet | Intracavernosal injection |
Alprostadil reported benefits
- Effective for erectile dysfunction
- Works independent of arousal
- Rapid onset
- Useful when oral PDE5 inhibitors fail
TriMix reported benefits
- Reliable erectile response
- Works when oral meds fail
- Rapid onset (5-15 min)
- Adjustable dosing
- No systemic cardiovascular effects
Related comparisons
Research and educational reference only. Not medical advice.